美罗培南个体化治疗慢性阻塞性肺病并发铜绿假单胞菌感染患者的研究

Study on individual treatment of meropenem for chronic obstructive pulmonary disease combined with Pseudomonas aeruginosainfection

目的探讨美罗培南个体化治疗慢性阻塞性肺疾病(COPD)并发铜绿假单胞菌感染患者的效果及安全性。方法将COPD并发铜绿假单胞菌感染的患者分成2组(个体化剂量组、标准剂量组)进行治疗,统计分析美罗培南对2组患者的疗效及安全性。结果个体化剂量组患者的美罗培南平均剂量为每12h(0.86±0.09)g,低于标准剂量组;个体化剂量组治疗的有效率为81.3%,2组间有效率的差异无统计学意义(P>0.05)。个体化剂量组患者不良反应的发生率低于标准剂量组(P<0.05),标准剂量治疗对肾功能有一定损伤,而个体化剂量能减轻美罗培南对肾功能的损伤。结论美罗培南的个体化给药不仅能在保证疗效的前提下提高治疗的安全性,还能降低对肾功能的损害。

Objective To investigate the efficacy and safety of meropenem for COPD combined with Pseudomonas aeruginosa in- fection. Methods The patients, suffered from COPD combined with Pseudomonas aeruginosa infection, were divided into two groups （dose group,standard dose group） according to the ways of treatment. Then we analyzed and evaluated the meropenem effi- cacy and safety in these two groups. Results Compared with the standard dose group,the dose of meropenem in personalized group was lower [-（0.86±0.09）g/12 hi. The effective rate of personalized dose group was a little higher than in the standard dose group, but there was no significant difference （P〈0.05）. The incidence of adverse reactions of personalized dose group was significantly lower than the standard-dose group （P〈0.05）. Considerate renal injury was found in standard-dose group while only a little was found in personalized dose group. Conclusion Personalized administration of meropenemn can improve the safety of therapy in the premise of ensuring efficacy,also it can reduce the renal damage.